Aprotinin is safe in pediatric patients undergoing cardiac surgery
Authors:
- Angela M. KelleAKAngela M. Kelle
- Robert D. StewartRSRobert D. Stewart
- Sunitha C. SureshSSSunitha C. Suresh
- Farah N. AliFAFarah N. Ali
- Richard A. CohnRCRichard A. Cohn
- Roopa SeshadriRSRoopa Seshadri
- Constantine MavroudisCMConstantine Mavroudis
- 1 December 2007
- journal article
- research article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 134 (6) , 1421-1428
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft SurgeryJAMA, 2007
- Characterizing the Inflammatory Response to Cardiopulmonary Bypass in ChildrenThe Annals of Thoracic Surgery, 2006
- The Risk Associated with Aprotinin in Cardiac SurgeryNew England Journal of Medicine, 2006
- Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trialsThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Aprotinin reduces operative closure time and blood product use after pediatric bypassThe Annals of Thoracic Surgery, 2003
- Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operationsThe Annals of Thoracic Surgery, 1998
- The Efficacy and Cost of Aprotinin in Children Undergoing Reoperative Open Heart SurgeryAnesthesia & Analgesia, 1996
- Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass–induced inflammation in humansThe Journal of Thoracic and Cardiovascular Surgery, 1995
- A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass GraftingCirculation, 1995
- Aprotinin therapy for reoperative myocardial revascularization: A placebo-controlled studyThe Annals of Thoracic Surgery, 1992